International Stem Cell Corp. Reports Q1 2026 Results with Ongoing Going Concern Warning and Critical Cash Position
ISCO has more than doubled off its 52-week low of $0.052.
Summary
International Stem Cell Corp. filed its Q1 2026 report, reiterating a 'going concern' warning due to insufficient cash, despite a slight reduction in net loss and a 9% increase in product sales.
Key Events · Earnings and Guidance · ISCO
-
Going Concern Warning Reiterated
Management and auditors continue to raise substantial doubt about the company's ability to continue as a going concern, citing insufficient cash to sustain operations for at least twelve months without additional financing.
-
Critical Cash Position
Cash balance decreased to $933,000 as of March 31, 2026, from $993,000 at December 31, 2025, indicating continued cash burn.
-
Reduced Net Loss
Net loss for Q1 2026 improved to $220,000, down from $256,000 in Q1 2025.
-
Increased Product Sales
Product sales rose by 9% to $2.315 million in Q1 2026, compared to $2.129 million in Q1 2025.
Analysis · ISCO · Life Sciences
International Stem Cell Corp. continues to face severe liquidity challenges, reiterating its 'going concern' warning. While the company reported a reduced net loss and increased product sales, its cash balance remains critically low at $933,000, and net cash provided by operating activities significantly decreased. The company explicitly states it lacks sufficient cash to sustain operations for the next twelve months without additional financing, highlighting its precarious financial state and continued reliance on related party debt.
At the time of this filing, ISCO was trading at $0.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.05 to $0.27. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.